Cargando…

P1464: DECREASING HPK1 EXPRESSION IN CD19 CAR-T CELLS: A NOVEL STRATEGY TO OVERCOME CHALLENGES OF CELL THERAPY FOR ADULT (R/R) B-ALL

Detalles Bibliográficos
Autores principales:	ZHANG, N., SI, J., LI, G., WANG, Y., LONG, F., WANG, T., SONG, Y., Dimitrov, D. S., LIAO, X., GAO, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431273/ http://dx.doi.org/10.1097/01.HS9.0000848712.54842.0a

Ejemplares similares

COLLABORATION AGREEMENT No. K 1464
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2008)

HPK1 tones down the T cell receptor
por: Leslie, Mitch
Publicado: (2011)

1464 The Marijuana Threat in Leukemia Patients
por: Rihana, Nancy, et al.
Publicado: (2014)

Layout and Performance of HPK Prototype LGAD Sensors for the High-Granularity Timing Detector
por: Yang, X., et al.
Publicado: (2020)

A Venetian "plague miracle" in 1464 and 1576.
por: Schupbach, W M
Publicado: (1976)

Radiation campaign of HPK prototype LGAD sensors for the High-Granularity Timing Detector (HGTD)
por: Shi, X., et al.
Publicado: (2020)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Evaluation of novel KEK/HPK n-in-p pixel sensors for ATLAS upgrade with testbeam
por: Nagai, R, et al.
Publicado: (2013)

The History and Diversity of Rice Domestication as Resolved From 1464 Complete Plastid Genomes
por: He, Wenchuang, et al.
Publicado: (2021)

Staphylococcus aureus subsp. anaerobius strain ST1464 genome sequence
por: Elbir, Haitham, et al.
Publicado: (2013)

PO-1464 Impact of COVID-19 on Radiation Oncology, an Austrian Experience
por: Mangesius, J., et al.
Publicado: (2021)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
por: Shiqi, Li, et al.
Publicado: (2023)

Evaluation of HPK $n^+$-$p$ planar pixel sensors for the CMS Phase-2 upgrade
por: Adam, W., et al.
Publicado: (2021)

Characterisation of 50 μm thick LGAD manufactured by FBK & HPK
por: Sola, V., et al.
Publicado: (2019)

P1464: CLINICAL COMPLICATIONS AMONG PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN GERMANY
por: Udeze, Chuka, et al.
Publicado: (2023)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

Homeodomain-Interacting Protein Kinase (HPK-1) regulates stress responses and ageing in C. elegans
por: Berber, Slavica, et al.
Publicado: (2016)

A perspective on HPK1 as a novel immuno-oncology drug target
por: Sawasdikosol, Sansana, et al.
Publicado: (2020)

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
por: You, Dan, et al.
Publicado: (2021)

Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening
por: Ge, Huizhen, et al.
Publicado: (2022)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Radiation Campaign of HPK Prototype LGAD sensors for the High-Granularity Timing Detector (HGTD)
por: Shi, Xin
Publicado: (2019)

Study of interpad-gap of HPK 3.1 production LGADs with Transient Current Technique
por: Bharthuar, Shudhashil, et al.
Publicado: (2020)

1464. The Clinical Features of Pneumonia Caused by Legionella pneumophila vs. Streptococcus pneumoniae: A Retrospective Study
por: Salahie, Sima, et al.
Publicado: (2018)

Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL
por: Sun, Ming, et al.
Publicado: (2021)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
por: Blanco, Belén, et al.
Publicado: (2022)

P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
por: Jain, N., et al.
Publicado: (2022)

P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)
por: Ghobadi, Armin, et al.
Publicado: (2023)

Cardiovascular disease market set to grow very slowly to $146.4 billion by 2022, says GBI Research
Publicado: (2016)

Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
por: Li, Xin, et al.
Publicado: (2021)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover, Maya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ceo9ls78po28ofs86q0j7v8pp2